BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 25244650)

  • 1. Emerging therapies for glioblastoma.
    Thomas AA; Brennan CW; DeAngelis LM; Omuro AM
    JAMA Neurol; 2014 Nov; 71(11):1437-44. PubMed ID: 25244650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunotherapy in brain tumors].
    De Carli E; Delion M; Rousseau A
    Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging therapies for glioblastoma: current state and future directions.
    Rong L; Li N; Zhang Z
    J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives on Microglia-Based Immune Therapies Against Glioblastoma.
    Rivera M; Bander ED; Cisse B
    World Neurosurg; 2021 Oct; 154():228-231. PubMed ID: 34583500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Problems of Glioblastoma Multiforme Drug Resistance.
    Stavrovskaya AA; Shushanov SS; Rybalkina EY
    Biochemistry (Mosc); 2016 Feb; 81(2):91-100. PubMed ID: 27260389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?
    Ferguson SD; Srinivasan VM; Ghali MG; Heimberger AB
    Immunotherapy; 2016; 8(4):413-23. PubMed ID: 26973123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential usefulness of radiosensitizers in glioblastoma.
    Harasaki Y; Waziri A
    Neurosurg Clin N Am; 2012 Jul; 23(3):429-37. PubMed ID: 22748655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Targeted therapy in glioblastoma: update and perspectives].
    Idbaih A; Duran-Peña A; Alentorn A
    Bull Acad Natl Med; 2015 Nov; 199(8-9):1323-1329. PubMed ID: 29874421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives for immunotherapy in glioblastoma treatment.
    Finocchiaro G; Pellegatta S
    Curr Opin Oncol; 2014 Nov; 26(6):608-14. PubMed ID: 25210870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The sodium pump could constitute a new target to combat glioblastomas].
    Lefranc F; Mijatovic T; Kiss R
    Bull Cancer; 2008 Mar; 95(3):271-81. PubMed ID: 18390407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.
    Murat A; Migliavacca E; Gorlia T; Lambiv WL; Shay T; Hamou MF; de Tribolet N; Regli L; Wick W; Kouwenhoven MC; Hainfellner JA; Heppner FL; Dietrich PY; Zimmer Y; Cairncross JG; Janzer RC; Domany E; Delorenzi M; Stupp R; Hegi ME
    J Clin Oncol; 2008 Jun; 26(18):3015-24. PubMed ID: 18565887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Insight: temozolomide as a treatment for malignant glioma--impact of a recent trial.
    Mason WP; Cairncross JG
    Nat Clin Pract Neurol; 2005 Dec; 1(2):88-95. PubMed ID: 16932504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing the immune system in glioblastoma.
    Brown NF; Carter TJ; Ottaviani D; Mulholland P
    Br J Cancer; 2018 Nov; 119(10):1171-1181. PubMed ID: 30393372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioblastoma and other malignant gliomas: a clinical review.
    Omuro A; DeAngelis LM
    JAMA; 2013 Nov; 310(17):1842-50. PubMed ID: 24193082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in therapy for glioblastoma.
    Clarke J; Butowski N; Chang S
    Arch Neurol; 2010 Mar; 67(3):279-83. PubMed ID: 20212224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.